1 / 26

Antimicrobial resistance surveillance in Ireland

Antimicrobial resistance surveillance in Ireland. Results of invasive Klebsiella pneumoniae infection (blood/CSF) surveillance, 2009 **** Data as of 01/12/2010 ****.

chi
Download Presentation

Antimicrobial resistance surveillance in Ireland

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Antimicrobial resistance surveillance in Ireland Results of invasive Klebsiella pneumoniae infection (blood/CSF) surveillance, 2009 **** Data as of 01/12/2010 **** Ireland is a member of the European Antimicrobial Resistance Surveillance Network (EARS-Net)

  2. EARS-Net K. pneumoniae:Objective and case definition Objective: • To determine the proportions of K. pneumoniae isolates from blood and/or CSF that are resistant to 4 key antibiotic classes: • Aminopenicillins (e.g. ampicillin) • 3rd Generation Cephalosporins (e.g. cefotaxime, ceftazidime) • Fluoroquinolones (e.g. ciprofloxacin) • Aminoglycosides (e.g. gentamicin, tobramycin, amikacin) Case definition: • EARS-Net collects data on the first invasive isolate (from blood/CSF) of K. pneumoniae per patient per quarter

  3. Caveats in interpreting EARS-Net data • Care must be exercised when interpreting the raw figures, i.e. increases in numbers of isolates, as the numbers of laboratories reporting to EARS-Net has increased over the years • EARS-Net data does not distinguish clinically significant isolates from contaminants • If a resistant isolate is identified subsequent to a susceptible one within the same quarter, then that isolate is not counted (and similarly if susceptible isolates is identified subsequent to resistant one)

  4. For further information on antimicrobial resistance and EARS-Net in Ireland, including quarterly and annual reports, plus reference/ resource material on the individual pathogens under surveillance, see: http://www.hpsc.ie/hpsc/A-Z/MicrobiologyAntimicrobialResistance/EuropeanAntimicrobialResistanceSurveillanceSystemEARSS/

  5. Antibiotic codes and abbreviations: AMK, Amikacin AMP, Ampicillin CTX, Cefotaxime CPD, Cefpodoxime CAZ, Ceftazidime CRO, Ceftriaxone CIP, Ciprofloxacin GEN, Gentamicin IPM, Imipenem MEM, Meropenem OFX, Ofloxacin TZP, Piperacillin-Tazobactam TOB, Tobramycin 3GC, 3rd-Generation Cephalosporin AMR, Antimicrobial Resistance KPN, K. pneumoniae ESBL, Extended-Spectrum Beta-Lactamase FQ-R, Fluoroquinolone-Resistant FQ-S, Fluoroquinolone-Susceptible MDR, Multi-Drug Resistance

  6. Numbers and resistance proportions of K. pneumoniaefrom invasive infection, 2006-2009 * Not all isolates tested

  7. Proportions of ESBLs and MDR among K. pneumoniaefrom invasive infection, 2006-2009 * Not all isolates tested

  8. Invasive K. pneumoniaeresistancetrends, 2006-2009 Number of laboratories participating by year-end and quarter are indicated above the bars

  9. Invasive K. pneumoniaeresistancetrends, 2006-2009: 3GCs and ESBLs Number of laboratories participating by year-end and quarter are indicated above the bars

  10. Invasive MDR K. pneumoniaetrends, 2006-2009 Number of laboratories participating by year-end and quarter are indicated above the bars

  11. Numbers and proportions of fluoroquinolone (FQ)-resistant invasive K. pneumoniaeinfection by hospital type, 2009

  12. Numbers and proportions of MDR invasive K. pneumoniaeinfection by hospital type, 2009

  13. Susceptibility data for invasive K. pneumoniaeisolates, 2009 (n=323)

  14. Resistance profiles of K. pneumoniaeisolates, 2009

  15. Age and sex distribution of patients with invasive K. pneumoniaeinfection, 2009

  16. Age and sex-specific incidence rates of invasive K. pneumoniaeinfection, 2009 ASIR, Age-Specific Incidence Rate (per 100,000 population)

  17. Mean, median, mode and range of ages of patients with invasive K. pneumoniaeinfection, 2009

  18. Sex distribution of patients with invasive K. pneumoniaeinfection, 2009 In patients with laboratory-confirmed invasive K. pneumoniae infection in 2009, males were approximately 1.3-times more likely to get an infection than females (significant, P=0.021).

  19. K. pneumoniae- distribution of 3GC (e.g. CTX or CAZ) resistance in EARSS/EARS-Net countries in 2009 Map downloaded from: http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx on 21/12/2010

  20. K. pneumoniae- distribution of 3GC (e.g. CTX or CAZ) resistance in EARSS countries in 2008 Map downloaded from http://www.rivm.nl/earss/database/ on 24/08/2009

  21. K. pneumoniae- distribution of fluoroquinolone (e.g. CIP) resistance in EARSS/EARS-Net countries in 2009 Map downloaded from: http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx on 21/12/2010

  22. K. pneumoniae- distribution of fluoroquinolone (e.g. CIP) resistance in EARSS countries in 2008 Map downloaded from http://www.rivm.nl/earss/database/ on 24/08/2009

  23. K. pneumoniae- distribution of aminoglycoside (e.g. GEN) resistance in EARSS/EARS-Net countries in 2009 Map downloaded from: http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx on 21/12/2010

  24. K. pneumoniae- distribution of aminoglycoside (e.g. GEN) resistance in EARSS countries in 2008 Map downloaded from http://www.rivm.nl/earss/database/ on 24/08/2009

  25. K. pneumoniae- distribution of carbapenems (e.g. MEM) resistance in EARSS/EARS-Net countries in 2009 Map downloaded from: http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx on 21/12/2010

  26. K. pneumoniae- distribution of carbapenems (e.g. MEM) resistance in EARSS countries in 2008 Map downloaded from http://www.rivm.nl/earss/database/ on 24/08/2009

More Related